Literature DB >> 9595390

Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis.

J A Grantham1, J A Schirger, E E Williamson, D M Heublein, P W Wennberg, M Kirchengast, K Muenter, T Subkowski, J C Burnett.   

Abstract

Endothelin-1 (ET-1) is a 21-amino-acid local and circulating factor whose plasma concentrations are increased in advanced atherosclerosis. ET-1 is cleaved from a prohormone (big ET-1) by endothelin-converting enzymes (ECEs) into the biologically active mature form which mediates vasoconstriction and cell proliferation. This study was designed to test by immunohistochemistry the hypothesis that ECE is present locally in the neointima of atherosclerotic vessels. Two groups of rabbits, control (n = 6) and cholesterol-fed (1% cholesterol diet for 8 weeks; n = 6) were sacrificed. Aortas were excised and divided for determination of tissue ET-1 concentration by RIA and immunohistochemical analysis of ECE. Vascular wall ET-1 was increased in the atherosclerotic aorta (6.1 +/- 0.8 vs. 9.8 +/- 0.9 pg/mg protein; p < 0.05), whereas circulating ET-1 concentrations were similar in the two groups (3.8 +/- 0.4 vs. 2.4 +/- 1.4 pg/ml). Immunostaining revealed the presence of ECE in endothelial and vascular smooth-muscle cells of the control group. Enhanced ECE immunoreactivity was present in atherosclerotic aortas, particularly in the neointimal macrophages and smooth-muscle cells. We conclude that local vascular wall, but not circulating ET-1, is increased in early atherosclerosis. In addition, ECE immunoreactivity is increased in early atherosclerosis and may therefore contribute to the generation of local ET-1 in early experimental atherosclerosis. These studies provide important insights into the regulation of ET-1 in early atherosclerosis, which may contribute to the elucidation of factors involved in the progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9595390     DOI: 10.1097/00005344-199800001-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver.

Authors:  Peter Johnström; Tim D Fryer; Hugh K Richards; Janet J Maguire; John C Clark; John D Pickard; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2010-02       Impact factor: 8.739

2.  Divergent roles of nitric oxide and rho kinase in vasomotor regulation of human retinal arterioles.

Authors:  Travis W Hein; Robert H Rosa; Zhaoxu Yuan; Elizabeth Roberts; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

Review 3.  Pharmacological hypothesis: Nitric oxide-induced inhibition of ADAM-17 activity as well as vesicle release can in turn prevent the production of soluble endothelin-converting enzyme.

Authors:  Sanjaya Kuruppu; Niwanthi W Rajapakse; Helena C Parkington; Ian Smith
Journal:  Pharmacol Res Perspect       Date:  2017-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.